U.S. Food and Drug Administration Approves BioMarin's Brineura (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
FDA approves BioMarin's Brineura for children under 3 with CLN2 disease, expanding its use to all ages, potentially delaying disease onset and slowing motor function decline.
Highlighted Terms
BioMarin Pharmaceutical Inc.BrineuraBatten Disease Support, Research, & Advocacy (BDSRA) FoundationBioMarin Medical InformationSecurities and Exchange CommissionCLN2 Diseasecerliponase alfaneuronal ceroid lipofuscinosis type 2WORLD SymposiumU.S. Food and Drug AdministrationBioMarin RareConnectionsFDA
Related News
U.S. Food and Drug Administration Approves BioMarin's Brineura (cerliponase alfa) for Children Under 3 Years with CLN2 Disease
FDA approves BioMarin's Brineura for children under 3 with CLN2 disease, expanding its use to all ages, potentially delaying disease onset and slowing motor function decline.